Matthias Hahn, n/a

Unit Head Respiratory GSA
Sanofi, Germany

Poster(s):

• (411) Real-world outcomes after 2 years of dupilumab therapy for severe asthma: the ProVENT study
  Wednesday, October 29, 2025